Aditxt IncADTX
Price$0.00

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $14.3K-89.3% YoYTTM through 31 Mar 2026
Net Income -$53.3MTTM through 31 Mar 2026
Free Cash Flow -$18.6MTTM through 31 Mar 2026

Margins

Current
Gross Margin23.6%
Operating Margin-12,782,137.0%
Net Margin-372,062.4%

Balance Sheet Health

Debt / Equity-0.09x
Current Ratio0.06x
Net Debt$4M
Cash & Equivalents$163K

Quality Metrics

Altman Z-Score-28.10
Piotroski F-Score2 / 9
FCF Margin-129,516.0%
Earnings-Beat Rate33.3%

Multi-Year Trend

Revenue
'21'22'23'24'25
FY2025: $3.2K
Diluted EPS
'21'22'23'24'25
FY2025: $-1,154.00

Dividend

No dividend

Capital Allocation

Capex Intensity95.9%

Segment Performance

SegmentRevenueYoYOutlook
Ignite Proteomics
View details

Aditxt signed a definitive agreement in June 2026 valuing Ignite Proteomics at approximately $150 million to accelerate its commercialization strategy.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.